{"prompt": "['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics, Inc.', 'Confidential', 'Page 18 of 92', 'CR845-CLIN3103', '7.0 Discussion and Justification of Study Design', '59', '7.1', 'Discussion of Study Design and Choice of Control Groups', '59', '7.2', 'Selection of Doses in the Study', '59', '7.3', 'Appropriateness of Measurements', '59', '8.0 Statistical Methods', '60', '8.1', 'General Considerations', '60', '8.2', 'Determination of Sample Size', '60', '8.3', 'Randomization', '61', '8.4', 'Interim Analysis', '62', '8.4.1', 'Sample Size Re-estimation', '62', '8.4.2', 'Safety Data Review', '63', '8.5', 'Analysis Populations', '63', '8.6', 'Statistical Summary and Analysis', '64', '8.6.1', 'Patient Disposition', '64', '8.6.2', 'Protocol Deviations', '64', '8.6.3', 'Demographic and Baseline Characteristics', '64', '8.6.4', 'Medical History', '64', '8.6.5', 'Prior and Concomitant Medications', '65', '8.6.6', 'Antipruritic Medication', '65', '8.7', 'Efficacy Analysis', '65', '8.7.1', 'Primary Efficacy Endpoint', '65', '8.7.2', 'Secondary Efficacy Endpoints', '67', '8.7.3', 'Hypothesis Testing Strategy', '69', '8.7.4', 'Additional Efficacy Endpoints', '70', '8.7.4.1', 'Itch-intensity Measures', '70', '8.7.4.2', 'Itch-related Quality-of-Life Measures', '71', '8.8', 'Safety Analysis', '71', '8.8.1', 'Exposure to Study Drug', '72', '8.8.2', 'Adverse Events', '72', '8.8.3', 'Clinical Laboratory Evaluations', '73', '8.8.4', 'Vital Signs and ECGs', '74', '10 September 2019', 'Version 2.2']['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics, Inc.', 'Confidential', 'Page 19 of 92', 'CR845-CLIN3103', '8.9', 'Additional Analyses', '75', '8.9.1', 'Inflammatory Biomarkers', '75', '8.9.2', 'Missed Dialysis Visits and Incidence of Infection', '75', '9.0 Quality Control and Quality Assurance', '76', '9.1', 'Study Monitoring Plan', '76', '9.2', 'Audits and Inspections', '76', '9.3', 'Data Collection, Validation, and Analysis', '77', '10.0 Ethics and Regulatory Compliance', '78', '10.1', 'Independent Ethics Committee or Institutional Review Board', '78', '10.2', 'Ethical Conduct of the Study', '78', '10.3', 'Informed Consent Process', '79', '10.4', 'Patient Confidentiality', '79', '11.0 Data Handling and Quality Assurance', '81', '12.0 Administrative Procedures', '82', '12.1', 'Protocol Adherence', '82', '12.2', 'Publication of Study Findings', '82', '13.0 References', '83', '14.0 Appendix', '85', '14.1', 'Appendix 1: New York Heart Association Classification of Heart Failure', '85', '14.2', 'Appendix 2: Worst Itching Intensity Numerical Rating Scale (NRS)', '86', '14.3', 'Appendix 3: Skindex-10 Scale', '87', '14.4', 'Appendix 4: 5-D Itch Scale', '88', '14.5', 'Appendix 5: Patient Global Impression of Change', '90', '14.6', 'Statistical Appendix', '91', '10 September 2019', 'Version 2.2']\n\n###\n\n", "completion": "END"}